Mentions
Extended reach
Total likes
Video views
AI synopsis
Overall, the discussions express strong agreement with the article's emphasis on inflammation as a key factor in cardiovascular risk, supported by technical references to the CANTOS trial and biological pathways. The tone is analytical and involved, with examples like references to IL-1β, CRP levels, and the implications of targeting inflammation, highlighting their perceived high impact on treatment approaches and research directions.
Most discussions highlight the significance of targeting inflammation, especially with Canakinumab, aligning with the research findings.
The conversations demonstrate high engagement, referencing multiple trials, biological pathways, and potential clinical implications.
Posts delve into detailed mechanisms like IL-1β, CRP, and immune pathways, indicating deep understanding and involvement.
Many discussions consider how these findings may influence future treatments and clinical practice, emphasizing the importance of inflammation in cardiovascular disease.
I think @NutritionMadeS3 is the king of cutting through the fog of misinformation on the Internet wrt heart disease risk. https://t.co/Jho8iojnLB
- is cholesterol associated with LESS death? - does HDL-cholesterol offset risk? - is oxidized LDL in blood (oxLDL) the "real" cause of heart disease? - LDL size - insulin resistance & CVD - inflammation & CVD - statin side effects etc https://t.co/HcC8FdaUiJ
Really like this channel. I recommend this video if you want insight on diet and nutrition: https://t.co/9iKzxnX2ai
More and more studies suggest that reducing inflammation is an important exis of heart disease prevention, similar to lipid markers https://t.co/xo4m522fLg
Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly cheaper than canakinumab #CANTOS https://t.co/zlNtt37N6s https://t.co/uETaokaQcY
full video: https://t.co/4rEtxW92ey
In this video, Dr. Sten Ekberg's cholesterol claims are critically analyzed against scientific evidence. Bempedoic acid, an ATP citrate lyase inhibitor, effectively reduces LDL cholesterol with fewer side effects…
Why do some individuals with high cholesterol avoid heart attacks while others with normal levels do not? This video explores the impact of DNA variations in the PCSK9 gene on LDL cholesterol levels and coronary heart…
What role does inflammation play in heart disease plaque growth and risk of heart attacks? If we keep inflammation in check, is that enough to reduce our heart disease risk? This video explores how inflammation…
Recent trial results indicate that colchicine can significantly lower cardiovascular event risks in patients with chronic coronary disease. The video discusses these findings and their implications for personalized care.
Peter Libby explains the role of inflammation in atherosclerotic cardiovascular disease and discusses how anti-inflammatory treatment, like canakinumab, may help reduce cardiovascular risk by lowering inflammation…
Prof Dr Dr Thimoteus Speer discusses the role of inflammatory signaling pathways in the high cardiovascular risk among CKD patients and explores how IL6 inhibition with Ziltivekimab, currently under investigation in the…
Dr. Steven Nissen discusses the impact of high-dose omega-3 fatty acids, particularly icosapent ethyl, on cardiovascular risk reduction in patients with high triglycerides, highlighting results from major trials showing…
@bioinvestor24 It’s not a new concept for Novartis! Remember the Cantos trial? Antiinflammatory therapy with canakinumab (anti IL-1β) for CVRR? https://t.co/6ve1uVqcmq
@VigilantFox This coming Aug. 7. Should be interesting.https://t.co/5XjKHyAipp
full video: https://t.co/4rEtxW92ey
@Banitoto Interesting landmark study. https://t.co/QzM0TOIiVc
@InPsx https://t.co/xqZ2Ui9ESz have a look at the video for more clarity
@delectblydelinq @Sisilmultisari @LDLSkeptic @KenDBerryMD When health influencers say that "cholesterol is healthy" they are ignoring hundreds of credible randomized controlled trials and studies showing that cholesterol in not "healthy." But people believe what they want to believe and ignore the evidence: https://t.co/C4DOXlXFUE
https://t.co/STRlkc1QLc
Background: Inflammation governs the progression of atherosclerotic lesions. On top of experimental, genetic and epidemiological data, #CANTOS (2017) showed that targeting inflammation among patients with atherosclerosis leads to decreases in CV risk https://t.co/03yokFz0t7 https://t.co/Qc1DjMOkDf
@PWoywodt @AnnetteBruchfe1 @monicafontana13 @ynptweets @ERAkidney https://t.co/h7ifAPAMlz
https://t.co/u4stZ88GFC
15/ There’s ++ interest in targeting thromboinflammation - shouldn’t affect haemostasis. CANTOS study (https://t.co/Esx1Q3L1h1) randomised pts with prev MI + CRP >2 to anti IL-1β, anakinra or placebo. Led to ⬆️recurrent cardiovasc events but ⬆️fatal infection – no effect on OS. https://t.co/5TVf38axuA
13/ There’s ++ interest in targeting thromboinflammation - shouldn’t affect haemostasis. CANTOS study (https://t.co/1799RCmWkH) randomised pts with prev MI + CRP >2 to anti IL-1β, anakinra or placebo. Led to ⬆️ recurrent cardiovasc events but ⬆️fatal infection – no effect on OS.
RT @FoolproofMaster: @Drlipid @theproof Whilst others with nearly 3 million youtube subscribers are confusing LDL particles with cells...…
カナキヌマブは抗腫瘍効果よりも心血管系疾患のCANTOS試験のほうが有名かもしれない。抗炎症効果で心筋梗塞既往があってCRP陽性を示す人の心血管・脳卒中イベントを減らしたらしい。ググると冠動脈疾患のデータの方がたくさん出てくる。／NEJM https://t.co/R4X8Di5H7W
@drewlocke @theproof https://t.co/lKIlRy9LZU and https://t.co/HcC8FdaUiJ
Cardiovascular disease (CVD) is an inflammatory issue not a high cholesterol one. An RCT showed by ↓ inflammation w/o lowering blood lipids, less to sig ↓ in CVD events. Reduce inflammation with diet & lifestyle, not the consequence with drugs #Gibraltar https://t.co/sDM6xRDtb8
Canakinumab demonstrated 15% lower risk of cardiovascular events than placebo. but unfortunately this antibody showed slightly higher incidence of fatal infections. (CANTOS trial)
@NutritionMadeS3 @DrNadolsky @TarbuckSam @BioLayne Haven’t watched this, but you also briefly touched it in your Sten Ekberg fact-check video. https://t.co/2XXeksFzkB
#statins & high #cholesterol EDUCATIONAL VIDEO Long but important with references https://t.co/xRrLWTdGgS
How NON-medical doctors nurses, laymen social media "experts"& lawyers like JFK Jr OFTEN misinterpret medical studies& give wrongful "advice" #cholesterol #lipids #HeartDisease #statins #PublicHealth #CAD It's actually complicated&most won't listen 2 this https://t.co/RUF8eafKOu
Dr Sten Ekberg gets fact-checked by MD PhD Doctor https://t.co/ONk6LuS6HO via @YouTube
RT @gunnar_heine: An academic giant at HOMe: Few days before #ESCCongress 23 it is an honor and pleasure to host Dr Peter Libby together w…
RT @gunnar_heine: An academic giant at HOMe: Few days before #ESCCongress 23 it is an honor and pleasure to host Dr Peter Libby together w…
RT @gunnar_heine: An academic giant at HOMe: Few days before #ESCCongress 23 it is an honor and pleasure to host Dr Peter Libby together w…
An academic giant at HOMe: Few days before #ESCCongress 23 it is an honor and pleasure to host Dr Peter Libby together with @floriancustodis @StephanSchirme2 @MarcusSaemann @dgfn_ev @oegnephro @com_SFNDT https://t.co/Tkk7XxzSoN
@AndeanFlora @drlipid has great content on this. statins can affect cholesterol production in the brain & good specialists consider it also see our content for effects on cognition which are often misstated on social media https://t.co/HcC8FdaUiJ (at 1h11min)
@MichaelJBlaha
@STC_BTC Dude. Don’t follow Dr. Ekberg. Facts check him: https://t.co/EWiyczm9dS
@Lpa_Doc @OxPL_apoB The word "Lp(a)" is not mentioned throughout the CANTOS protocol
RT @NutritionMadeS3: @Nutradvance @_advg_ we recently went over this exact FAQ of inflammation in CVD https://t.co/4rEtxW92ey inflammation…
@Nutradvance @_advg_ we recently went over this exact FAQ of inflammation in CVD https://t.co/4rEtxW92ey inflammation is obviously involved but the common idea that "hypercholesterolemia is ok as long as inflammatory markers are low" is almost certainly a misconception
@JohnnyScott234 with statins it's possible. mixed evidence but for secondary prevention (history of hem stroke) there's a possibility covered here (toward the end) https://t.co/HcC8FdaUiJ
@steross245 @Conigman @shiv_twitts we also covered it here in the 1st 10mins https://t.co/HcC8FdaUiJ Peter Attia also had a recent article explaining this. it´s possibly the #1 FAQ about cholesterol on social media
RT @NutritionMadeS3: full video: https://t.co/4rEtxW92ey
@WFPB_Longevity @SentientBlobBob Ik u r joking but still posting this: https://t.co/NrHnyASDKr https://t.co/aC1zX2mGXR
From our colleague Gil Carvalho MD, Ph.D https://t.co/9qj6ZDoisb
@drpablocorral 1/"Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering." https://t.co/k4UlvQAo90
@lipo_fan @ChristofferBN @NutritionMadeS3 @WillBrink @Drlipid @joerogan @ZDoggMD So targeting inflammation does lower the rate of recurrent CVD but (of course) it doesn't prevent it completely. Btw. have a look at the participants' characteristics. They have low LDL but high TG. https://t.co/g93CHLIq84 https://t.co/WiCPTFZ97o
@Drlipid People get tunnel vision, even those with the sci/med background to know better. Focusing on inflammation to the exclusion of apoB is poor science. Still, inflammation appears a therapeutic target: https://t.co/k4UlvQAo90
RT @NutritionMadeS3: full video: https://t.co/4rEtxW92ey
@galaxysplain @Drlipid @PrimaryCarePAC @NutritionMadeS3 @joerogan @ZDoggMD "...targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering" https://t.co/k4UlvQAo90
@Drlipid @_RadicalHealth_ @NutritionMadeS3 @joerogan @ZDoggMD For those interested: https://t.co/k4UlvQAo90
Gil Carvalho explains environmental factors to decrease personal risk for ascvd. Lowering Apo-B over a prolonged therapeutic duration is ideal. Optimally, the lower the Apo-B the better and of course this depends on baseline risk factors! https://t.co/9qj6ZDoisb
RT @NutritionMadeS3: full video: https://t.co/4rEtxW92ey
RT @NutritionMadeS3: full video: https://t.co/4rEtxW92ey
full video: https://t.co/4rEtxW92ey
Really like this channel. I recommend this video if you want insight on diet and nutrition: https://t.co/9iKzxnX2ai
@ChristofferBN @ThelastStyleb16 @MohammedAlo @BradStanfieldMD @MichaelAlbertMD @DBelardoMD we reviewed the evidence on statins and stroke (of the 2 kinds) here: https://t.co/HcC8FdaUiJ (toward the end) this is specific to statins, not having lower cholesterol levels genetically or via lifestyle
Dr Sten Ekberg gets fact-checked by MD PhD Doctor https://t.co/RlsUlJmrye via @YouTube
RT @simondankel: Landmark CANTOS trial: "Antiinflammatory therapy targeting interleukin-1β innate immunity pathway with canakinumab [...] l…
RT @simondankel: Landmark CANTOS trial: "Antiinflammatory therapy targeting interleukin-1β innate immunity pathway with canakinumab [...] l…
Landmark CANTOS trial: "Antiinflammatory therapy targeting interleukin-1β innate immunity pathway with canakinumab [...] led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering" #paradigmshift https://t.co/sVlYuftNeS https://t.co/NJgUDTUzZ3
@ivanprieto8 Yes, my episode was only 23 minutes, so I referenced this one from @NutritionMadeS3 , which is 82 minutes and covers all the things: https://t.co/Jho8iojnLB
@MasalaFry69 @marelit @BigJonHookEm @OptumisticAg https://t.co/WhyeCUAaJP Apo(a) too https://t.co/fLVTYtvF3V https://t.co/uyV6ILhX7o
@NutritionMadeS3 u make a lot of good videos, but I have to give u a special shoutout for this one. I can think of few others out there that do a better job at exposing the difference btwn good quality scientific analysis and, well, bs. Thnx as always. https://t.co/bxASm7sZoj
Dr Sten Ekberg gets fact-checked by MD PhD Doctor https://t.co/J0iqUfeO9K via @YouTube
@josiahgarber @holmanm @NutritionMadeS3 1:11:50 https://t.co/UvCRGuuvZr
RT @agingdoc1: Gil’s @NutritionMadeS3 (@YouTube @YouTubeCreators) respond to @drstenekberg‘s video
RT @NutritionMadeS3: - is cholesterol associated with LESS death? - does HDL-cholesterol offset risk? - is oxidized LDL in blood (oxLDL…
Great information about ASCVD risk factors and prevention in this video by @NutritionMadeS3 https://t.co/drRiwVaY2F
Gil’s @NutritionMadeS3 (@YouTube @YouTubeCreators) respond to @drstenekberg‘s video
RT @PlantChompers: I think @NutritionMadeS3 is the king of cutting through the fog of misinformation on the Internet wrt heart disease risk…
RT @PlantChompers: I think @NutritionMadeS3 is the king of cutting through the fog of misinformation on the Internet wrt heart disease risk…
I think @NutritionMadeS3 is the king of cutting through the fog of misinformation on the Internet wrt heart disease risk. https://t.co/Jho8iojnLB
@Mangan150 https://t.co/7H3OQO05eU this is the video... I refering to....
@Drlipid @theproof Whilst others with nearly 3 million youtube subscribers are confusing LDL particles with cells... @NutritionMadeS3 is doing a great job at clarifying so much confusion... Claim timestamped. Just click the video. https://t.co/B9TAYzWd3q
RT @NutritionMadeS3: - is cholesterol associated with LESS death? - does HDL-cholesterol offset risk? - is oxidized LDL in blood (oxLDL…
For the love of science, stop listening to Dr. Eric Berg. While you're at it, also ignore Dr. Ken Berry. They both ignore the strongest evidence and provide misleading information on the causes of heart disease. Please listen to scientists and experts. https://t.co/0380IAJEYT
@ppoppopower 그사람 틀린 말할때도 많어! 형부한테 이거 보여드려 (근데 브로콜리는 좋은거 맞음 ㅋㅋㅋㅋㅋ) https://t.co/p2uPzvKS2S
@NutritionMadeS3's reaction video
Dr Sten Ekberg gets fact-checked by MD PhD Doctor https://t.co/MLDF3oSdsK via @YouTube
@holmanm Check this propganda out Marion: https://t.co/95VTSAjW0z
- is cholesterol associated with LESS death? - does HDL-cholesterol offset risk? - is oxidized LDL in blood (oxLDL) the "real" cause of heart disease? - LDL size - insulin resistance & CVD - inflammation & CVD - statin side effects etc https://t.co/HcC8FdaUiJ
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (2017) #CANTOS https://t.co/OGWZQ8dFml https://t.co/dPLJ7gxZwT
@frondynamics @leiatheinvestor Todo estudo envolve financiamento. Inclusive os que não dão certo. Por exemplo esse daqui: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. Esse estudo deu foi patrocinado pela indústria, deu ruim, mesmo assim foi publicado.
https://t.co/jZIpHzAJLk https://t.co/OSvH0jKM5S https://t.co/xXFKnfHH5t
@SBdoc33 @PD_Perls @ImprovePd Justification for CANTOS https://t.co/lQETldHdrJ and subsequent colchicine trials came from https://t.co/zBHI6a1irz
9/ For a median follow-up of 3.7 years, Canakinumab reduced recurrent major adverse cardiovascular events w/ unaffected LDL levels. https://t.co/ain7dYx3Wu
Reducing CVD events without reducing LDL
@DrPaulMason @LDLSkeptic @BenBikmanPhD “The CANTOS trial [has] taken a drug that doesn’t affect cholesterol levels but………also reduce rates of cardiovascular events,...” https://t.co/Rj3SqB5QEI https://t.co/LnM3lXqlFd
@JeremySussman @hmkyale @djc795 interleukin-1β. https://t.co/cMIaLWTaPF
@BiotechObserver A drug that lowered interleukin-1 beta lowered CV events. So that seems like a relevant marker. https://t.co/7HaY7z0o8y
RT @FPoppelaars: Today, I discussed the CANTOS trial @NEJM with my scientific colleagues @SciFiMed: https://t.co/HdylkTuWtp I noticed that…
RT @FPoppelaars: Today, I discussed the CANTOS trial @NEJM with my scientific colleagues @SciFiMed: https://t.co/HdylkTuWtp I noticed that…
Today, I discussed the CANTOS trial @NEJM with my scientific colleagues @SciFiMed: https://t.co/HdylkTuWtp I noticed that they did not share my enthusiasm for this LANDMARK paper, so i'll try again on #MedTwitter! Check out the
RT @ck_eternity_: More and more studies suggest that reducing inflammation is an important exis of heart disease prevention, similar to lip…
RT @ck_eternity_: More and more studies suggest that reducing inflammation is an important exis of heart disease prevention, similar to lip…
RT @ck_eternity_: More and more studies suggest that reducing inflammation is an important exis of heart disease prevention, similar to lip…
More and more studies suggest that reducing inflammation is an important exis of heart disease prevention, similar to lipid markers https://t.co/xo4m522fLg
RT @healthmisinfo: More directly, CANTOS, which tested whether directly reducing inflammation in the body would help prevent and treat hear…
More directly, CANTOS, which tested whether directly reducing inflammation in the body would help prevent and treat heart disease, resoundingly showed that yes indeed, inflammation does play an important role in the development of cardiovascular disease. https://t.co/s5tWrukaaZ
2/ There’s an interesting backstory here - this trial comes in the wake of the largely unsuccessful CANTOS (https://t.co/93hYXblNf4) & CIRT trials (https://t.co/wgXWmGNIrx) for IL1 and MTX, respectively
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | NEJM $200,000 for IL-1 inhibitor post MI with modest benefits at the price of this increased infections. https://t.co/otJkKCCsEb https://t.co/OCEOZMWLP8
Interesting clinical trial (CANTOS) looking at immunotherapy with canakinumab (150 mg q3months) in a reduction in cardiovascular events. https://t.co/n3SmM8vDmQ
⚠️Reducción de los eventos cardiovasculares mediante un antiinflamatorio SIN variación en los niveles de LDL-c. https://t.co/vkg7uWrfeK
@ToniElFisico https://t.co/T3AuGjf3wP ahí va
@Hokkis @JACCJournals They published it in the main paper — https://t.co/ZxDtuuy1uz https://t.co/mxNPZpbj30
@DrNadolsky @ZKForTre @DaveKeto @gerdosi @The_Nutrivore @Gearoidmuar @erreyedoc @johnzahorik @FatEmperor @LukeEdwards504 @julie_eye @DrDeborahMD @Drlipid @DrPaulMason @nationallipid @DoctorTro @PeterAttiaMD @kevinnbass @mdavidsonmd @SethJBaumMD @Lipoprotein @lipiddoc @LipidCNS @DaveDixonPharmD @NeilFlochMD @drpablocorral @DrTomFrieden @NYTHealth @JoanneKenen @JamesTodaroMD "Canakinumab was associated with a higher incidence of fatal infection than was placebo." Long way to go. https://t.co/mccfhuwUi5
@ZKForTre @DaveKeto @gerdosi @The_Nutrivore @Gearoidmuar @erreyedoc @brianedwardsmd @johnzahorik @FatEmperor @LukeEdwards504 @julie_eye @DrDeborahMD @Drlipid @DrPaulMason @nationallipid @DoctorTro @PeterAttiaMD @kevinnbass @mdavidsonmd @SethJBaumMD @Lipoprotein @lipiddoc @LipidCNS @DaveDixonPharmD @NeilFlochMD @drpablocorral @DrTomFrieden @NYTHealth @JoanneKenen @JamesTodaroMD I think I’m gathering what the discussion is. A lot of good info about the topic in these two recent trials https://t.co/oHdluIcIvI https://t.co/HsMXVhzlmW
Er... "Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway... led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering..." https://t.co/CXTycJSmRJ @FatEmperor @DaveKeto @siobhan_huggins
10/14 anti-inflammatory rx demonstrated favorable effects w/ Canakinumab induced IL1B inhibition in the CANTOS trial; but not w/ Methotrexate in the CIRT trial https://t.co/nKjAwE3XAC https://t.co/2XAgRJWqA8
Everybody seems to love #canakinumab Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | NEJM https://t.co/9wMRHv8UD7
@beatricinha2 https://t.co/HIV2fDiAUt
@ogi_gajic @DrSamuelBrown @timothygirard @DrJMLuther @DMAronoff @toddrice_ICU @medevidenceblog Ridker has studied IL6 blocking. Statins have the same effect as a novel IL6 blocker. Less harmful than steroids as well. https://t.co/QkLvDSoSRv
Hasta que llegó el estudio CANTOS con Canakinumab y demostró efectos benéficos, sin embargo aumentaba la incidencia de infecciones fatales con respecto al placebo. https://t.co/l8baLpJwUW
RT @AkhmetzhanG: @ArturoGiacaman @PCRonline @Julio_Farjat @DavidLBrownMD @EuroInterventio @NEJM @Dr_DanMD @INC_CathLab @aayshacader @yeh_ja…
RT @AkhmetzhanG: @ArturoGiacaman @PCRonline @Julio_Farjat @DavidLBrownMD @EuroInterventio @NEJM @Dr_DanMD @INC_CathLab @aayshacader @yeh_ja…
@ArturoGiacaman @PCRonline @Julio_Farjat @DavidLBrownMD @EuroInterventio @NEJM @Dr_DanMD @INC_CathLab @aayshacader @yeh_james3 @RandyKoh24 @UjjwalRastogiMD Hi, Arturo! Agree further research would be of importance. Stratification of pts based on inflammatory biomarkers (such as CRP https://t.co/XbmifrADto) could help identify responders to colchicine. Or colchicine could have noninflammatory mechanism (but! https://t.co/sNjoJd0OgF)
@M_Elraggal
https://t.co/8DJuOYSbBy This trial from 2017. Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering.
RT @hjanders_hans: Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly c…
RT @hjanders_hans: Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly c…
RT @hjanders_hans: Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly c…
@matthewherper As I’m sure you’re aware, have been other big MACE RCTs w anti-inflammatories that show similar efficacy (eg see CANTOS). And Sek showed Mendelian Rand data that inflammation genes are important in MI risk. But it doesn’t seem to change clinical practice? https://t.co/eeL1al13WU
RT @hjanders_hans: Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly c…
RT @hjanders_hans: Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly c…
RT @hjanders_hans: Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly c…
Another trial showing benefits from targeting chronic inflammation in cardiovascular disease. Colchicine is certainly cheaper than canakinumab #CANTOS https://t.co/zlNtt37N6s https://t.co/uETaokaQcY
RT @CarlosdelRio7: Canakinunab is the correct answer based on CANTOS trial published in @NEJM https://t.co/1qx6qj42Yl
Canakinunab is the correct answer based on CANTOS trial published in @NEJM https://t.co/1qx6qj42Yl
@Mangan150 The CANTOS study (using anti-IL-1) supports the role of inflammation in CVD https://t.co/JlIGuuHGX2
@EBRheum You mean IL-1 worked for CVD.... CANTOS. https://t.co/JlIGuuq65u
(A quick aside: blockage of this innate immune response is likely why the following studies showed positive results: - CANTOS - using IL-1 https://t.co/JlIGuuq65u - LoDoCo - using colchicine https://t.co/bdUIOqezRI ) /7
https://t.co/T22cv8agjJ
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease | NEJM https://t.co/bTNEOwbu6n
CM